Whether you’re using GLP-1s yourself or supporting patients/clients who are, this 4-part video series breaks down the real science, the risks of one-size-fits-all protocols, and what a more strategic approach looks like.
There is increasing discussion about GLP-1 Agonists—a class of peptides commonly used in treatments for weight management and diabetes, including medications such as Ozempic, Wegovy and Mounjaro. However, not every media report reflects rigorous scientific research. Join me as we review current data and examine the scientific evidence behind these compounds. You’ll receive a new video each day along with informative emails.
Explore potential benefits of GLP1 Agonists that extend beyond weight management. These peptides are under active research for their effects on brain health, cardiovascular health, inflammation and more, and current studies continue to examine their broader applications.
Examine the evidence behind GLP1 Agonists to gain a balanced understanding of common concerns and misconceptions. In this series, I review the available scientific data to help clarify what the research indicates about their use.
The way these medications are introduced, monitored, and supported can shape both your results and your experience. In this video series, you’ll learn how thoughtful, individualized approaches may help reduce side effects and support long-term metabolic health—especially when paired with a comprehensive longevity plan.
You’ve heard the hype. Now get the facts. Designed for GenXers 40+, this free series explains what GLP-1s really do in the body—beyond the headlines and the hype—so you can make empowered, well-informed decisions.